• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Viking Global Investors Lp disposed of 6,642,700 shares (SEC Form 4)

    2/28/24 4:28:49 PM ET
    $RYZB
    Get the next $RYZB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    VIKING GLOBAL INVESTORS LP

    (Last) (First) (Middle)
    600 WASHINGTON BLVD.
    FLOOR 11

    (Street)
    STAMFORD CT 06901

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    RayzeBio, Inc. [ RYZB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/26/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/26/2024 J(1) 4,899,144 D (1) 0 I See Explanation of Responses(2)(3)(4)(6)
    Common Stock 02/26/2024 J(1) 1,743,556 D (1) 0 I See Explanation of Responses(2)(3)(5)(6)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    VIKING GLOBAL INVESTORS LP

    (Last) (First) (Middle)
    600 WASHINGTON BLVD.
    FLOOR 11

    (Street)
    STAMFORD CT 06901

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Viking Global Opportunities Parent GP LLC

    (Last) (First) (Middle)
    600 WASHINGTON BLVD.
    FLOOR 11

    (Street)
    STAMFORD CT 06901

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Viking Global Opportunities GP LLC

    (Last) (First) (Middle)
    600 WASHINGTON BLVD.
    FLOOR 11

    (Street)
    STAMFORD CT 06901

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Viking Global Opportunities Portfolio GP LLC

    (Last) (First) (Middle)
    600 WASHINGTON BLVD.
    FLOOR 11

    (Street)
    STAMFORD CT 06901

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Viking Global Opportunities Illiquid Investments Sub-Master LP

    (Last) (First) (Middle)
    600 WASHINGTON BLVD.
    FLOOR 11

    (Street)
    STAMFORD CT 06901

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    HALVORSEN OLE ANDREAS

    (Last) (First) (Middle)
    600 WASHINGTON BLVD.
    FLOOR 11

    (Street)
    STAMFORD CT 06901

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Ott David C.

    (Last) (First) (Middle)
    600 WASHINGTON BLVD.
    FLOOR 11

    (Street)
    STAMFORD CT 06901

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Shabet Rose Sharon

    (Last) (First) (Middle)
    600 WASHINGTON BLVD.
    FLOOR 11

    (Street)
    STAMFORD CT 06901

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Upon completion of the merger of the Issuer with a wholly-owned subsidiary of Bristol-Myers Squibb Company on February 26, 2024, these shares of common stock of the Issuer were automatically converted into the right to receive $62.50 per share in cash, without interest and subject to any applicable withholding of taxes.
    2. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), and Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), the sole member of Viking Global Opportunities GP LLC ("Opportunities GP"), the sole member of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), the general partner of Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund"). Opportunities Parent is also the sole member of Viking Global Opportunities Drawdown GP LLC ("VGOD GP"), the sole member of Viking Global Opportunities Drawdown Portfolio GP LLC ("VGOD Portfolio GP"), the general partner of Viking Global Opportunities Drawdown (Aggregator) LP ("VGOD").
    3. VGI provides managerial services to various investment funds and vehicles, including Opportunities Fund and VGOD. VGI, Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, Opportunities Fund, VGOD GP, VGOD Portfolio GP, VGOD, Mr. Halvorsen, Mr. Ott and Ms. Shabet are, collectively, the "Reporting Persons". Each of VGI, Opportunities Parent, Mr. Halvorsen, Mr. Ott and Ms. Shabet may be deemed to beneficially own all of the securities reported on this form.
    4. These securities were held directly by Opportunities Fund. Because of the relationship between Opportunities Portfolio GP, Opportunities GP, Opportunities Parent and Opportunities Fund, each of Opportunities Portfolio GP, Opportunities GP and Opportunities Parent may be deemed to beneficially own the securities held directly by Opportunities Fund.
    5. These securities were held directly by VGOD. Because of the relationship between VGOD Portfolio GP, VGOD GP, Opportunities Parent and VGOD, each of VGOD Portfolio GP, VGOD GP and Opportunities Parent may be deemed to beneficially own the securities held directly by VGOD.
    6. The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
    Remarks:
    (7) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. Because no more than 10 reporting persons can file any one Form 4 through the SEC's EDGAR system, VGOD GP, VGOD Portfolio GP and VGOD have jointly filed with the other Reporting Persons on a separate Form 4 filing submitted on the same day hereof. (8) Scott M. Hendler is signing on behalf of Mr. Halvorsen, Mr. Ott and Ms. Shabet, each individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to authorization and designation letters dated February 9, 2021, which were filed with the Securities and Exchange Commission on June 7, 2021.
    /s/ Scott M. Hendler signing on behalf of O. Andreas Halvorsen (7)(8) 02/28/2024
    /s/ Scott M. Hendler signing on behalf of David C. Ott (7)(8) 02/28/2024
    /s/ Scott M. Hendler signing on behalf of Rose S. Shabet (7)(8) 02/28/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RYZB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RYZB

    DatePrice TargetRatingAnalyst
    10/11/2023Outperform
    Evercore ISI
    10/10/2023$29.00Buy
    Truist
    10/10/2023$35.00Buy
    Jefferies
    10/10/2023$30.00Overweight
    JP Morgan
    10/6/2023Outperform
    William Blair
    More analyst ratings

    $RYZB
    Financials

    Live finance-specific insights

    See more
    • Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

      Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "By strengthening and further diversifying our oncology pipeline bey

      2/26/24 8:35:00 AM ET
      $BMY
      $RYZB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

      Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State of the Art Radiopharmaceutical Manufacturing Capabilities PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which

      12/26/23 7:13:25 AM ET
      $BMY
      $RYZB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

       Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State-of-the-Art Radiopharmaceutical Manufacturing Capabilities Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per shar

      12/26/23 6:59:00 AM ET
      $BMY
      $RYZB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYZB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Viking Global Investors Lp disposed of 6,642,700 shares (SEC Form 4)

      4 - RayzeBio, Inc. (0001825367) (Issuer)

      2/28/24 4:28:49 PM ET
      $RYZB
    • Viking Global Investors Lp disposed of 6,642,700 shares (SEC Form 4)

      4 - RayzeBio, Inc. (0001825367) (Issuer)

      2/28/24 4:30:12 PM ET
      $RYZB
    • SEC Form 4 filed by Oliger Christy J.

      4 - RayzeBio, Inc. (0001825367) (Issuer)

      2/27/24 5:14:07 PM ET
      $RYZB

    $RYZB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RayzeBio Inc. (Amendment)

      SC 13G/A - RayzeBio, Inc. (0001825367) (Subject)

      2/28/24 4:28:08 PM ET
      $RYZB

    $RYZB
    Leadership Updates

    Live Leadership Updates

    See more
    • RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

      SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Tim Van Hauwermeiren to its board of directors. As co-founder and CEO of argenx, Tim has built a reputation for his strong execution and innovation, leading argenx from early-stage development into a global immunology company. "RayzeBio has the potential to transform the oncology treatment landscape through targeted radiopharmaceuticals. I see a lot of parallels between RayzeBio and argenx and look forward to leveraging my experience to help RayzeBio unlock the full pote

      11/1/23 6:00:00 AM ET
      $RYZB

    $RYZB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axonis Therapeutics Announces $115 Million Series A Financing

      -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

      10/30/24 6:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

      - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

      8/1/24 8:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

      Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "By strengthening and further diversifying our oncology pipeline bey

      2/26/24 8:35:00 AM ET
      $BMY
      $RYZB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYZB
    SEC Filings

    See more
    • SEC Form 15-12G filed by RayzeBio Inc.

      15-12G - RayzeBio, Inc. (0001825367) (Filer)

      3/7/24 4:07:39 PM ET
      $RYZB
    • SEC Form S-8 POS filed by RayzeBio Inc.

      S-8 POS - RayzeBio, Inc. (0001825367) (Filer)

      2/26/24 9:20:50 AM ET
      $RYZB
    • RayzeBio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits

      8-K - RayzeBio, Inc. (0001825367) (Filer)

      2/26/24 9:20:10 AM ET
      $RYZB

    $RYZB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on RayzeBio

      Evercore ISI initiated coverage of RayzeBio with a rating of Outperform

      10/11/23 7:52:46 AM ET
      $RYZB
    • Truist initiated coverage on RayzeBio with a new price target

      Truist initiated coverage of RayzeBio with a rating of Buy and set a new price target of $29.00

      10/10/23 7:32:40 AM ET
      $RYZB
    • Jefferies initiated coverage on RayzeBio with a new price target

      Jefferies initiated coverage of RayzeBio with a rating of Buy and set a new price target of $35.00

      10/10/23 7:31:44 AM ET
      $RYZB